
Kura Oncology: Good Cash, Some Good Data, A Few Problems
Andrew Brookes/Image Source via Getty Images I covered Kura Oncology, Inc. (NASDAQ:KURA) two years ago, when I said that, although I like the company’s science, per se, lead asset tipifarnib does not have adequate patent […]